[2] The selectivity profile of Ipamorelin is a key reason it is commonly discussed as a partner in this stack over older GHRPs
The publisher, authors, editors, syndication partners, and all distribution platforms make no warranties or representations regarding the completeness, accuracy, or reliability of the information and expressly disclaim any and all liability for any losses, damages, or harm resulting from the use or misuse of any product referenced in this content
"Body composition outcomes in obesity pharmacotherapy: clinical significance and measurement challenges." Reviews in Endocrine and Metabolic Disorders
Martinez DR, Schafer A, Gavitt TD, Mallory ML, Lee E, Catanzaro NJ, et al
This genomic footprint has no equivalent in published palmitoyl peptide research